ClinicalTrials.gg
TerminatedNCT04905121Updated Oct 12, 2022

Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

A Phase 1 interventional study of Psilocybin in Short Lasting Unilateral Neuralgiform Headache Attacks, sponsored by Beckley Psytech Limited. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-12.

Sponsored by Beckley Psytech Limited (part of Eli Lilly and Company) · Phase 1, Interventional, and Treatment

Why this study was terminated
Unable to recruit patient population

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Headache by Eli Lilly and Company — none open to participants now, 2 under way, 2 of them phase 3. Headache · Eli Lilly and Company.

Enrollment
16th of 16
4 · median 312
Started
2021
the only one that year
Phase 1
2 of 16
none open now
Registered
16th of 16
by date

Among the 16 studies in Headache by Eli Lilly and Company, this one is the 16th largest by enrollment, is the only one that started in 2021, is one of 2 in phase 1, and was the 16th registered.

Headache

762 studies on the registry are indexed under Headache; 134 are open to participants now.

Browse Headache studies →

Open to participants now

None of the 16 studies in Headache by Eli Lilly and Company is open now. The open studies under Headache, anywhere →

Who these studies take

Of the 83 Headache studies recruiting now, 30 (36%) set no upper age limit and 44 (53%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Headache by Eli Lilly and Company as a file.
02

Study summary

This exploratory open-label phase 1b, ascending dose study is to evaluate the effects of psilocybin on cognition in patients with Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

Read the detailed description

The study aims to:

Determine the safety and tolerability of psilocybin when administered to patients with chronic SUNHA

Determine the effects of psilocybin on cognition when administered to patients with chronic SUNHA

Explore the change in frequency, duration, and intensity of headache attacks with escalating doses of psilocybin in patients with chronic SUNHA

03

Conditions studied

  • Short Lasting Unilateral Neuralgiform Headache Attacks

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

* Diagnosed with chronic SUNHA

Exclusion criteria

Exclusion Criteria:

* Other comorbidities

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Psilocybin

    Drug: Psilocybin

Interventions

  • Psilocybin will be provided in form of dry filled capsules and administered orally in three ascending doses

06

What researchers measure

Primary outcomes

  1. Percentage of patients with treatment emergent AEs (TEAES)

    Time frame: From first dose administered through to the last follow up visit, approximately 39 days

  2. Treatment-related changes in Paired Associates Learning (PAL) scores and evaluation of dose response

    Time frame: From first dose administered until the las dose administered, approximately 11 days

  3. Treatment-related changes in Spatial Working Memory (SWM) scores and evaluation of dose response

    Time frame: From first dose administered until the las dose administered, approximately 11 days

  4. Treatment-related changes in Reaction Time Index (RTI) scores and evaluation of dose response

    Time frame: From first dose administered until the las dose administered, approximately 11 days

  5. Treatment-related changes in Rapid Visual Information Processing (RVP) scores and evaluation of dose response

    Time frame: From first dose administered until the las dose administered, approximately 11 days

  6. Change in frequency of headache attacks

    Time frame: From screening until the follow up visit, approximately 39 days

  7. Change in duration of headache attacks

    Time frame: From screening until the follow up visit, approximately 39 days

  8. Change in intensity of headache attacks

    Patients will complete a diary on a daily basis and capture the intensity of their headaches by assigning a score out of 10 where 0 is pain free and 10 is excruciating pain

    Time frame: From screening until the follow up visit, approximately 39 days

07

Study locations

1 site
  • King's College London
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Due to the UK GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Apr 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2021
First posted
May 27, 2021
StartActual
Aug 11, 2021
Primary completionActual
Apr 22, 2022
CompletionActual
Apr 22, 2022
Last update
Oct 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04905121
Responsible party
Sponsor
First posted
May 27, 2021
Start date
Aug 11, 2021
Primary completion
Apr 22, 2022
Completion
Apr 22, 2022
Last update
Oct 12, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion